Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Call Options Transaction History
Slate Path Capital LP
- $5.36 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARWR
# of Institutions
338Shares Held
103MCall Options Held
953KPut Options Held
263K-
Vanguard Group Inc Valley Forge, PA16MShares$662 Million0.01% of portfolio
-
Black Rock Inc. New York, NY15.7MShares$647 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.9MShares$450 Million5.14% of portfolio
-
State Street Corp Boston, MA6.4MShares$264 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.13MShares$129 Million0.01% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $4.37B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...